Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01203358 · ClinicalTrials.gov registry record · Phase 2
Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome
A Phase 2 study, sponsored by NICHD Neonatal Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 617
- Enrollment target
NCT01203358 is a Phase 2 study that has completed, run by NICHD Neonatal Research Network. The registered enrollment target is 617 participants.
The verdict
NCT01203358, a Phase 2 study, has completed, sponsored by NICHD Neonatal Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 617 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.
Interventions
- DRUG Exosurf
- DRUG Survanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 617 participants |
| Start Date | 1991-01 |
| Est. Completion | 1992-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01203358
The ClinicalTrials.gov registry entry for NCT01203358 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 617 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NICHD Neonatal Research Network, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exosurf is the first listed.
NCT01203358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01203358 about?
NCT01203358 is a clinical study titled "Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome". The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.
What is the current status of trial NCT01203358?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 617 participants. The study started on 1991-01. Estimated completion is 1992-01.
What interventions are being tested in trial NCT01203358?
The interventions under investigation include: Exosurf (DRUG), Survanta (DRUG).
Who is sponsoring clinical trial NCT01203358?
This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.